Nuwellis, Inc. (Nasdaq: NUWE) announced unaudited preliminary revenue results for its second quarter ended June 30, 2026, showing year-over-year growth of 14% for the quarter and 20% for the first half of 2026.

The Minneapolis-based medical technology company attributed the results to its Aquadex Ultrafiltration platform. The financial figures are unaudited and subject to adjustment as the company completes its quarterly review and finalizes financial statements for filing with its Form 10-Q.

"Revenue growth of 20% during the first half of 2026 demonstrates the increasing adoption of Aquadex and the progress we are making in executing our long-term growth strategy," said Mike McCormick, Nuwellis Chief Executive Officer.

Nuwellis said it plans to report full second-quarter financial results before U.S. market open on August 13, 2026, followed by a conference call and webcast at 9:00 a.m. Eastern time.